Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

@article{Coles2012AlemtuzumabFP,
  title={Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.},
  author={Alasdair John Coles and Cary L Twyman and Douglas L. Arnold and Jeffrey A. Cohen and Christian Confavreux and Edward J. Fox and H C Hartung and Eva Kubala Havrdov{\'a} and Krzysztof W. Selmaj and Howard L. Weiner and Tamara H Miller and Elizabeth H. Fisher and Rupert Sandbrink and Stephen L. Lake and David H. Margolin and Pedro Oyuela and Michael A. Panzara and D. Alastair S. Compston},
  journal={Lancet},
  year={2012},
  volume={380 9856},
  pages={1829-39}
}
BACKGROUND The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment. METHODS In our 2 year, rater-masked, randomised controlled phase 3 trial, we enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one relapse on… CONTINUE READING
Highly Influential
This paper has highly influenced 31 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 28 times over the past 90 days. VIEW TWEETS
247 Citations
35 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 247 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Alemtuzumab more eff ective than interferon beta 1 a at 5 - year follow - up of CAMMS 223 Clinical Trial

  • AJ Coles, E Fox, A Vladic
  • Sci Transl Med
  • 2012

Similar Papers

Loading similar papers…